US5654451B1
(en)
|
1993-01-14 |
2000-02-22 |
Magainin Pharma |
Amino acids and peptides having modified c-terminals and modified n-terminals
|
CA2153987A1
(en)
|
1993-01-14 |
1994-07-21 |
U. Prasad Kari |
Amino acids and peptides having modified terminals
|
EP1532118A2
(en)
|
2002-07-05 |
2005-05-25 |
Axxima Pharmaceuticals Aktiengesellschaft |
Imidazole compounds for the treatment of hepatitis c virus infections
|
WO2004014852A2
(en)
|
2002-08-12 |
2004-02-19 |
Bristol-Myers Squibb Company |
Iminothiazolidinones as inhibitors of hcv replication
|
DE102004036971B4
(de)
|
2004-07-30 |
2009-07-30 |
Advanced Micro Devices, Inc., Sunnyvale |
Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
|
WO2006022442A1
(ja)
|
2004-08-24 |
2006-03-02 |
Santen Pharmaceutical Co., Ltd. |
ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
|
WO2006093867A1
(en)
|
2005-02-28 |
2006-09-08 |
The Rockefeller University |
Structure of the hepatitits c virus ns5a protein
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
SI1940786T1
(sl)
|
2005-09-16 |
2010-11-30 |
Arrow Therapeutics Ltd |
Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C
|
WO2007058384A1
(en)
|
2005-11-17 |
2007-05-24 |
Osaka University |
Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
|
WO2007076034A2
(en)
|
2005-12-21 |
2007-07-05 |
Abbott Laboratories |
Anti-viral compounds
|
US7915411B2
(en)
|
2005-12-21 |
2011-03-29 |
Abbott Laboratories |
Anti-viral compounds
|
SG133452A1
(en)
|
2005-12-30 |
2007-07-30 |
Novartis Ag |
Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
|
BRPI0712806A2
(pt)
|
2006-05-30 |
2012-10-23 |
Arrow Therapeutics Ltd |
uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8303944B2
(en)
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100158862A1
(en)
|
2006-08-11 |
2010-06-24 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CN101558059B
(zh)
*
|
2006-08-11 |
2014-12-03 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
US7745636B2
(en)
|
2006-08-11 |
2010-06-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100055071A1
(en)
|
2006-11-21 |
2010-03-04 |
Martin Robert Leivers |
Anti-Viral Compounds
|
CA2672737A1
(en)
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
WO2009102694A1
(en)
|
2008-02-12 |
2009-08-20 |
Bristol-Myers Squibb Company |
Heterocyclic derivatives as hepatitis c virus inhibitors
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8729077B2
(en)
|
2008-11-28 |
2014-05-20 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
CN104163816A
(zh)
|
2008-12-03 |
2014-11-26 |
普雷西迪奥制药公司 |
Hcv ns5a的抑制剂
|
SG171890A1
(en)
|
2008-12-03 |
2011-07-28 |
Presidio Pharmaceuticals Inc |
Inhibitors of hcv ns5a
|
JP2012513409A
(ja)
|
2008-12-23 |
2012-06-14 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
EP2393359A4
(en)
|
2009-02-09 |
2012-10-03 |
Enanta Pharm Inc |
COMPOUND DIBENZIMIDAZOLE DERIVATIVES
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
WO2010094977A1
(en)
|
2009-02-23 |
2010-08-26 |
Arrow Therapeutics Limited |
Novel biphenyl compounds useful for the treatment of hepatitis c
|
WO2010096777A1
(en)
|
2009-02-23 |
2010-08-26 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
CN102427731B
(zh)
|
2009-02-27 |
2015-05-13 |
英安塔制药有限公司 |
丙型肝炎病毒抑制剂
|
CN103880862B
(zh)
|
2009-03-27 |
2018-09-25 |
默沙东公司 |
丙型肝炎病毒复制的抑制剂
|
EP2410843A4
(en)
|
2009-03-27 |
2012-08-08 |
Presidio Pharmaceuticals Inc |
FUSIONED CORE INHIBITORS OF HEPATITIS C
|
US8709999B2
(en)
|
2009-03-27 |
2014-04-29 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
TWI476190B
(zh)
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US20110237636A1
(en)
|
2009-03-30 |
2011-09-29 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TW201038559A
(en)
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010120935A1
(en)
|
2009-04-15 |
2010-10-21 |
Abbott Laboratories |
Anti-viral compounds
|
EP2421855A1
(en)
|
2009-04-24 |
2012-02-29 |
Tibotec Pharmaceuticals |
Diaryl ethers
|
CA2760205A1
(en)
|
2009-05-12 |
2010-11-18 |
Schering Corporation |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
JP5582662B2
(ja)
|
2009-05-13 |
2014-09-03 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
US8211928B2
(en)
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8138215B2
(en)
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2762885A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
|
EP2435424B1
(en)
|
2009-05-29 |
2015-01-21 |
Merck Sharp & Dohme Corp. |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
MY186633A
(en)
|
2009-06-11 |
2021-07-31 |
Abbvie Bahamas Ltd |
Heterocyclic compounds as inhibitors of hepatitis c virus (hcv)
|
US9394279B2
(en)
|
2009-06-11 |
2016-07-19 |
Abbvie Inc. |
Anti-viral compounds
|
WO2010148006A1
(en)
|
2009-06-16 |
2010-12-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
MX2012000695A
(es)
|
2009-07-16 |
2012-06-12 |
Vertex Pharma |
Análogos de bencimidazol para el tratamiento o la prevención de infecciones por flavivirus.
|
CA2768637A1
(en)
|
2009-08-07 |
2011-02-10 |
Tibotec Pharmaceuticals |
Phenyl ethynyl derivatives as hepatitis c virus inhibitors
|
CN102471324B
(zh)
|
2009-08-07 |
2014-12-17 |
泰博特克药品公司 |
作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
|
BR112012004969A2
(pt)
|
2009-09-03 |
2019-09-24 |
Tibotec Pharm Ltd |
derivados de bis-benzimidazol
|
US8344155B2
(en)
|
2009-09-04 |
2013-01-01 |
Glaxosmith Kline Llc |
Chemical compounds
|
US9156818B2
(en)
|
2009-09-11 |
2015-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
EP2475254A4
(en)
|
2009-09-11 |
2013-05-22 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011050146A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxosmithkline Llc |
Chemical compounds
|
UA108211C2
(uk)
|
2009-11-04 |
2015-04-10 |
Янссен Рід Айрленд |
Бензімідазолімідазольні похідні
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110269956A1
(en)
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
JP2013512246A
(ja)
|
2009-11-25 |
2013-04-11 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
|
US8415482B2
(en)
|
2009-12-04 |
2013-04-09 |
National Health Research Institutes |
Proline derivatives
|
WO2011081918A1
(en)
|
2009-12-14 |
2011-07-07 |
Enanta Pharmaceuticals, Inc |
Hepatitis c virus inhibitors
|
US8377980B2
(en)
*
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN104530079B
(zh)
|
2009-12-18 |
2017-10-20 |
北京凯因科技股份有限公司 |
C型肝炎病毒复制的新型抑制剂
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
WO2011087740A1
(en)
|
2009-12-22 |
2011-07-21 |
Schering Corporation |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
KR20120130173A
(ko)
|
2009-12-24 |
2012-11-29 |
버텍스 파마슈티칼스 인코포레이티드 |
플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
|
US8362020B2
(en)
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2011091446A1
(en)
|
2010-01-22 |
2011-07-28 |
Glaxosmithkline Llc |
Chemical compounds
|
US8785487B2
(en)
|
2010-01-25 |
2014-07-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
EP2528926A4
(en)
|
2010-01-28 |
2013-06-19 |
Boehringer Ingelheim Int |
HEPATITIS C INHIBITOR COMPOUNDS
|
US8623814B2
(en)
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
US8178531B2
(en)
|
2010-02-23 |
2012-05-15 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
CA2791630A1
(en)
|
2010-03-04 |
2011-09-09 |
Enanta Pharmaceuticals, Inc. |
Combination pharmaceutical agents as inhibitors of hcv replication
|
AU2011224698A1
(en)
|
2010-03-09 |
2012-11-01 |
Merck Sharp & Dohme Corp. |
Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
|
EP2550268A1
(en)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
JP2013522375A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
EP2555622A4
(en)
|
2010-04-09 |
2013-09-18 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
WO2011146401A1
(en)
|
2010-05-17 |
2011-11-24 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
WO2011149856A1
(en)
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2011150243A1
(en)
|
2010-05-28 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
US8778938B2
(en)
*
|
2010-06-04 |
2014-07-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
AR081848A1
(es)
|
2010-06-09 |
2012-10-24 |
Presidio Pharmaceuticals Inc |
Inhibidores de la proteina ns5a del vhc
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
WO2012003642A1
(en)
|
2010-07-09 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and use thereof for treating viral diseases
|
CA2805440A1
(en)
|
2010-07-26 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
EA023642B1
(ru)
|
2010-07-26 |
2016-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Гетеробициклические производные в качестве ингибиторов hcv
|
SG187183A1
(en)
|
2010-08-04 |
2013-02-28 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US20120196794A1
(en)
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
US20120195857A1
(en)
*
|
2010-08-12 |
2012-08-02 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
EP2603080A4
(en)
|
2010-08-12 |
2014-01-22 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
CA2809261A1
(en)
|
2010-08-26 |
2012-03-01 |
Rfs Pharma, Llc |
Potent and selective inhibitors of hepatitis c virus
|
US8822520B2
(en)
|
2010-09-22 |
2014-09-02 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
WO2012040924A1
(en)
|
2010-09-29 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
|
WO2012041227A1
(en)
|
2010-09-29 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds for treating hepatitis c viral infection
|
EP2621501A4
(en)
|
2010-09-29 |
2014-04-09 |
Merck Sharp & Dohme |
POLYCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS FOR THEIR USE IN THE TREATMENT OF VIRAL DISEASES
|
EP2621931A4
(en)
|
2010-09-29 |
2014-03-19 |
Merck Sharp & Dohme |
TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
|
WO2012040923A1
(en)
|
2010-09-29 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
|
EP2621279B1
(en)
|
2010-09-29 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
US8999967B2
(en)
|
2010-09-29 |
2015-04-07 |
Presidio Pharmaceuticals, Inc. |
Tricyclic fused ring inhibitors of hepatitis C
|
WO2012048421A1
(en)
|
2010-10-14 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
CA2814534A1
(en)
|
2010-11-04 |
2012-05-10 |
Theravance, Inc. |
Novel inhibitors of hepatitis c virus
|
CA3095528C
(en)
|
2010-11-17 |
2023-07-18 |
Gilead Pharmasset Llc |
Antiviral compounds
|
RU2452735C1
(ru)
|
2010-11-30 |
2012-06-10 |
Александр Васильевич Иващенко |
Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
|
EP2651927A4
(en)
|
2010-12-15 |
2014-06-04 |
Abbvie Inc |
ANTIVIRAL CONNECTIONS
|
EP2651928A4
(en)
|
2010-12-15 |
2014-06-18 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
US20140343286A1
(en)
|
2010-12-15 |
2014-11-20 |
Allan C. Krueger |
Anti-viral compounds
|
WO2012083053A2
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
EP2651920A4
(en)
|
2010-12-15 |
2014-12-17 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
US20140364616A1
(en)
|
2010-12-15 |
2014-12-11 |
Abbvie Inc. |
Anti-viral compounds
|
WO2012083164A1
(en)
|
2010-12-16 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
WO2012083170A1
(en)
|
2010-12-16 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
WO2012087976A2
(en)
|
2010-12-21 |
2012-06-28 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
WO2012122716A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9546160B2
(en)
|
2011-05-12 |
2017-01-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2714693A4
(en)
|
2011-05-26 |
2014-12-10 |
Abbvie Inc |
ANTIVIRAL COMPOUNDS
|
WO2012162578A2
(en)
|
2011-05-26 |
2012-11-29 |
Abbvie Inc. |
Anti-viral compounds
|
AU2012262338B2
(en)
|
2011-05-27 |
2016-12-08 |
Achillion Pharmaceuticals, Inc. |
Substituted Aliphanes, Cyclophanes, Heteraphanes, Heterophanes, Hetero-Heteraphanes and Metallocenes Useful for Treating HCV Infections
|
WO2012175581A1
(en)
|
2011-06-24 |
2012-12-27 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
JP2014520822A
(ja)
|
2011-07-09 |
2014-08-25 |
スンシネ ルアケ プハルマ カンパニー リミテッド |
C型肝炎ウイルス阻害剤としてのスピロ化合物
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|